Cynomolgus BTLA Protein
Catalog No: BTLA-CP001
- Species
- Cynomolgus
- Expression System
- HEK293
- Tag
- His
- Activity
- Activity verified
Product overview
Recombinant Cynomolgus BTLA Protein is expressed in HEK293 cells with a His tag at the C-terminus. It contains amino acid residues Lys31-Pro152 (UniProt accession: A0A2K5W7M7).
Product Details
- Molecular Aliases
- CD272; BTLA; BTLA1; FLJ16065; MGC129743
- Protein Length
- Lys31-Pro152
- Expression System
- HEK293
- Theoretical Molecular Weight
- The protein has a predicted MW of 15.04 kDa. Due to glycosylation, the protein migrates to 35-40 kDa based on Bis-Tris PAGE result.
- Purity
- > 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC
- Endotoxin
- Less than 1 EU per μg by the LAL method.
- Buffer / Formulation
- Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
- State
- Lyophilized
- Storage Conditions
- -20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
- Reconstitution Advice
- Dissolve the lyophilized protein in distilled water. Please refer to the Certificate of Analysis for detailed instructions.
Data Display
Cynomolgus BTLA on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
The purity of Cynomolgus BTLA is greater than 95% as determined by SEC-HPLC.
Immobilized Cynomolgus BTLA, His Tag at 1μg/ml (100μl/well) on the plate. Dose response curve for Anti-BTLA Antibody, hFc Tag with the EC50 of 4.9ng/ml determined by ELISA. (QC Test)
Loaded Anti-BTLA Antibody, hFc Tag on ProA-Biosensor can bind Cynomolgus BTLA, His Tag with an affinity constant of 3.47 nM as determined in BLI assay.
Background
B- and T-lymphocyte attenuator (BTLA; CD272) is a 35 kDa type I transmembrane glycoprotein in the CD28 family of T cell costimulatory molecules. BTLA is a inhibitory receptor on lymphocytes that negatively regulates antigen receptor signaling via PTPN6/SHP-1 and PTPN11/SHP-2. BTLA may interact in cis (on the same cell) or in trans (on other cells) with TNFRSF14.
References
- Haymaker C L, Wu R C, Ritthipichai K, et al. BTLA marks a less-differentiated tumor-infiltrating lymphocyte subset in melanoma with enhanced survival properties[J]. OncoImmunology, 2015, 4(8):e1014246. Note: HPLC results always come from liquid protein, due to absorption peak interference of trehalose in lyophilized powder.
Have questions about this product?
Our technical team can help with product selection, application questions and order support.